Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31496519 | 0.78 | HDAC6 (0.32) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL25036963 | 0.78 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL2622073 | 0.77 | HDAC6 (0.38) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL956549 | 0.77 | ALDH1A1 (0.42) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL28234844 | 0.76 | HDAC6 (0.33) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL17162509 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL2754735 | 0.76 | HDAC6 (0.37) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL22604686 | 0.74 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL1810981 | 0.74 | HDAC6 (0.36) | HDAC6HDAC1HDAC2L3MBTL1 | |
| SCHEMBL4928353 | 0.74 | CA12 (0.34) | HDAC6HDAC1HDAC2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9603829-B2 | HSP90 inhibitors with modified toxicity | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-28 | — | — | US | claimed |
| EP-2190291-B1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | UNIV COLORADO REGENTS (US) | 2015-10-14 | — | — | EP | claimed |
| US-20140315845-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE | 2014-10-23 | — | — | US | claimed |
| US-8551964-B2 | Hsp90 inhibitors with modified toxicity | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2013-10-08 | — | — | US | claimed |
| WO-2013074695-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2013-05-23 | — | — | WO | claimed |
| US-20120022011-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2012-01-26 | — | — | US | claimed |
| EP-2190291-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | The Regents of the University of Colorado (US) | 2010-06-02 | — | — | EP | claimed |
| US-7608611-B2 | Hsp90 inhibitors, methods of making and uses therefor | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-10-27 | — | — | US | claimed |
| EP-1863769-A4 | HSP90 INHIBITORS, METHODS OF MAKING AND USES THEREFOR | UNIV COLORADO (US) | 2009-03-18 | — | — | EP | claimed |
| WO-2009026548-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-02-26 | — | — | WO | claimed |
| EP-1863769-A2 | HSP90 INHIBITORS, METHODS OF MAKING AND USES THEREFOR | The Board of Regents of the University of Colorado (US) | 2007-12-12 | — | — | EP | claimed |
| WO-2006098761-A2 | HSP90 INHIBITORS, METHODS OF MAKING AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-09-21 | — | — | WO | claimed |
| US-20060205705-A1 | Hsp90 inhibitors, methods of making and uses therefor | UNIVERSITY OF COLORADO (US) | 2006-09-14 | — | — | US | claimed |
| US-9676708-B2 | Controlled HNO release through intramolecular cyclization-elimination | THE JOHNS HOPKINS UNIVERSITY (US) | 2017-06-13 | — | — | US | disclosed |
| US-9603829-B2 | HSP90 inhibitors with modified toxicity | THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE (US) | 2017-03-28 | — | — | US | disclosed |
| US-20150291519-A1 | CONTROLLED HNO RELEASE THROUGH INTRAMOLECULAR CYCLIZATION-ELIMINATION | NATIONAL SCIENCE FOUNDATION | 2015-10-15 | — | — | US | disclosed |
| WO-2009026548-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2009-02-26 | — | — | WO | disclosed |
| EP-1863769-A2 | HSP90 INHIBITORS, METHODS OF MAKING AND USES THEREFOR | The Board of Regents of the University of Colorado (US) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006098761-A2 | HSP90 INHIBITORS, METHODS OF MAKING AND USES THEREFOR | THE REGENTS OF THE UNIVERSITY OF COLORADO (US) | 2006-09-21 | — | — | WO | disclosed |
| US-20060205705-A1 | Hsp90 inhibitors, methods of making and uses therefor | UNIVERSITY OF COLORADO (US) | 2006-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060205705-A1 | Hsp90 inhibitors, methods of making and uses therefor | HSP90AB1, HSP90B1, HSP90AA1 | HDAC6 222/4885HDAC1 551/4885HDAC2 1223/4885 |
| US-20120022011-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | HSP90AB1, HSP90B1, HSP90AA1 | HDAC6 27/4885HDAC1 138/4885HDAC2 314/4885 |
| US-20140315845-A1 | HSP90 INHIBITORS WITH MODIFIED TOXICITY | HSP90AB1, HSP90AA1, HSP90B1 | HDAC6 24/4885HDAC1 362/4885HDAC2 432/4885 |
| US-20150291519-A1 | CONTROLLED HNO RELEASE THROUGH INTRAMOLECULAR CYCLIZATION-ELIMINATION | APEH, HNMT, HAAO | HDAC6 1180/4885HDAC1 2007/4885HDAC2 1403/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.